Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Open-label,Multicenter Phase II Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Chemotherapy in Women With HER2 Positive Early Stage or Locally Advanced Breast Cancer

NCT03847818 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT03847818
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03847818 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Open-label,Multicenter Phase II Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Chemotherapy in Women With HER2 Positive Early Stage or Locally Advanced Breast Cancer
Lead sponsor
Shandong University
Phase
Not applicable
Overall status
Unknown status
Start date
March 1, 2019
Completion date
February 28, 2021
Enrollment
268 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer